Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Hypersensitivity Reactions ◽

Second Line ◽

230 A Phase II Study of Pegylated Liposomal Doxorubicin Combined with Cyclophosphamide / 5-fluorouracil as Second Line Chemotherapy in Patients with Metastatic Breast Cancer Who Failed Previous Taxane-based Treatment

European Journal of Cancer ◽

10.1016/s0959-8049(12)70298-8 ◽

2012 ◽

Vol 48 ◽

pp. S109-S110

Author(s):

H.K. Chang ◽

Y.C. Lin ◽

K.M. Rau ◽

Y.Y. Chen ◽

K.D. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Second Line ◽

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-007-0259-0 ◽

2007 ◽

Vol 134 (2) ◽

pp. 125-135 ◽

Cited By ~ 9

Author(s):

Martina Baur ◽

Allan T. van Oosterom ◽

Véronique Diéras ◽

Michele Tubiana-Hulin ◽

R. Charles Coombes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Second Line ◽

A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e13059 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e13059-e13059 ◽

Cited By ~ 2

Author(s):

Mitsuhiko Iwamoto ◽

Kosei Kimura ◽

Satoru Tanaka ◽

Daigo Yamamoto ◽

Katsuhide Yoshidome ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Second Line ◽

Patient Reported ◽

Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2

European Journal of Cancer ◽

10.1016/s0959-8049(99)81709-2 ◽

1999 ◽

Vol 35 ◽

pp. S322

Author(s):

H.A. Burris ◽

J.D. Hainesworth ◽

K. Albain ◽

M. Huntington ◽

F.A. Greco ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Second Line ◽

A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-018-3567-y ◽

2018 ◽

Vol 81 (5) ◽

pp. 923-933

Author(s):

Kosei Kimura ◽

Mitsuhiko Iwamoto ◽

Satoru Tanaka ◽

Daigo Yamamoto ◽

Katsuhide Yoshidome ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Second Line ◽

Patient Reported ◽

0187 Weekly docetaxel with or without gemcitabine as second line chemotherapy in paclitaxel pretreated patients with metastatic breast cancer: A randomised phase II study conducted by the Hellenic Co-operative oncology group

The Breast ◽

10.1016/s0960-9776(09)70210-3 ◽

2009 ◽

Vol 18 ◽

pp. S66

Author(s):

F. Zagouri ◽

A. Bamias ◽

P. Papakostas ◽

A. Karadimou ◽

E. Bournakis ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Oncology Group ◽

Weekly Docetaxel ◽

Pretreated Patients ◽

Abstract PS13-31: Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study)

10.1158/1538-7445.sabcs20-ps13-31 ◽

2021 ◽

Author(s):

Yuri Fujimoto ◽

Yuichiro Kikawa ◽

Takeshi Kotake ◽

Shigeru Tsuyuki ◽

Sachiko Takahara ◽

...

Keyword(s):

Breast Cancer ◽

Observational Study ◽

Prospective Observational Study ◽

Metastatic Breast ◽

Second Line ◽

406 POSTER Safety and efficacy of sunitinib malate (SU11248) as second-line therapy in metastatic breast cancer (MBC) patients: preliminary results from a phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80704-9 ◽

2005 ◽

Vol 3 (2) ◽

pp. 113-114 ◽

Cited By ~ 3

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Sunitinib Malate ◽

Safety And Efficacy ◽

Line Therapy

Cost-Effectiveness Analysis of Fulvestrant in the Treatment of Metastatic Breast Cancer in Second-Line Chemotherapy

Value in Health ◽

10.1016/j.jval.2014.08.2289 ◽

2014 ◽

Vol 17 (7) ◽

pp. A637

Author(s):

I. Krysanov ◽

V. Krysanova

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Effectiveness Analysis ◽

Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

Oncology ◽

10.1159/000236021 ◽

2009 ◽

Vol 77 (3-4) ◽

pp. 212-216 ◽

Cited By ~ 5

Author(s):

Christos A. Papadimitriou ◽

Haralambos Kalofonos ◽

Flora Zagouri ◽

Pavlos Papakostas ◽

George Bozas ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Oncology Group ◽

Weekly Docetaxel ◽

Randomized Phase Ii ◽

Pretreated Patients ◽